MannKind Corporation 10-Q Summary: First Quarter 2013
Business Context and Reporting Period
MannKind is a development-stage biopharmaceutical company focused on diabetes therapies and its Technosphere platform. Its lead candidate, AFREZZA inhalation insulin, was in late-stage clinical development and had not been approved or commercialized. The filing covers the three months ended March 31, 2013, with unaudited financial statements.
Key Financial Metrics
| Metric | Q1 2013 | Q1 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $26.4 million | $24.2 million |
| General and administrative expense | $10.0 million | $9.8 million |
| Total operating expenses | $36.4 million | $33.9 million |
| Loss from operations | $36.4 million | $33.9 million |
| Net loss | $41.0 million | $38.2 million |
| Net loss per share | $0.15 | $0.27 |
| Cash used in operating activities | $32.0 million | $32.5 million |
Net loss per share improved primarily because the weighted-average share count increased to 280.1 million from 143.2 million. Profitability and operating margins were not meaningful because the company generated no revenue and remained loss-making.
- Cash and cash equivalents declined to $28.0 million at March 31, 2013, from $61.8 million at December 31, 2012.
- Total assets were $215.2 million and total liabilities were $362.0 million, resulting in stockholders’ deficit of $146.8 million.
- Senior convertible notes had a carrying value of $212.4 million, comprising $115.0 million due December 2013 and $100.0 million due August 2015.
- The Mann Group related-party note payable was $119.6 million, with $125.4 million of additional borrowing capacity available through September 30, 2013. The borrowing rate was 4.5% at quarter-end.
- Investing cash use was $1.5 million, primarily for property and equipment, including manufacturing-line expansion.
- Financing cash flow was negative $0.3 million, compared with $86.5 million of financing inflows in Q1 2012.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 9% to $26.4 million. Clinical costs rose as the company progressed studies 171 and 175, while manufacturing and research costs declined.
- General and administrative expense increased 3% despite lower salaries and legal costs, primarily because stock-based compensation increased.
- Stock-based compensation increased to $5.2 million from $2.9 million. The company granted 5.846 million performance-based restricted stock units tied to AFREZZA regulatory and business-development milestones.
- Net loss increased by $2.8 million, reflecting higher operating expenses and substantially lower other income than in Q1 2012.
- Operating cash burn improved modestly by $0.5 million, but cash declined substantially because there were no comparable equity-financing proceeds during Q1 2013.
Guidance, Outlook, Risks, and Unusual Items
- Management expected to complete two Phase 3 AFREZZA studies in the second quarter of 2013 and submit results to the FDA as an NDA amendment in the fourth quarter of 2013. The filing cautions that the data may not support approval and that the FDA could require additional studies.
- Management expected overall research and development and general and administrative expenses to decline in 2013 as clinical trials conclude and cost-cutting measures take effect.
- Management stated that existing cash, available Mann Group borrowings, and potential ATM proceeds were expected to fund planned operations through at least the third quarter of 2013.
- The company entered into ATM agreements in March 2013 permitting aggregate sales of up to $50.0 million of common stock, but no shares had been issued under the agreements as of the filing.
- The company disclosed substantial doubt about its ability to continue as a going concern. Cash on hand was insufficient to repay the $115.0 million 2013 notes at maturity, and additional capital, refinancing, collaboration proceeds, asset sales, or other funding would be required.
- Potential funding from exercise of October 2012 warrants was uncertain; the filing estimated up to $89.7 million of gross proceeds if the public offering warrants were fully exercised.
- Key risks include failure to obtain FDA approval, inadequate clinical results, additional trial requirements, manufacturing and supplier challenges, inability to secure a commercialization partner, substantial dilution from future financing or conversions, and repayment or refinancing risk related to debt.
- No legal proceedings were reported as material, no defaults upon senior securities were reported, and no off-balance-sheet arrangements existed.
Most Important Facts for Investors to Verify
- Whether the AFREZZA Phase 3 studies met their targeted completion timetable and produced data sufficient for the planned FDA submission.
- The company’s ability to raise or refinance the funds needed for the $115.0 million December 2013 note maturity and ongoing operating cash needs.
- Actual utilization and availability under the Mann Group credit facility and the terms of any subsequent related-party financing.
- Whether the ATM facility, warrant exercises, equity issuance, or strategic collaboration generated additional liquidity and the resulting dilution.
- Changes in AFREZZA regulatory status, manufacturing readiness, clinical-trial costs, and the company’s going-concern assessment.